Semaglutide Plus Therapy Cuts Heavy Drinking by 41%, Landmark Lancet Study Finds
NIH-funded trial shows GLP-1 drug combined with cognitive behavioral therapy significantly reduces heavy drinking days in patients with alcohol use disorder and obesity.
May 2, 20265 min read